Prosensa Holding N.V. Announces Closing of Initial Public Offering
LEIDEN, the Netherlands--(BUSINESS WIRE)--
Prosensa Holding N.V. ("Prosensa") announced today the closing of its
previously announced initial public offering of 6,900,000 of its
ordinary shares at a price of $13.00 per share (including an additional
900,000 ordinary shares pursuant to the exercise of the over-allotment
option by the underwriters). The ordinary shares began trading on the
Nasdaq Global Market on June 28, 2013 under the symbol "RNA".
Prosensa intends to use the proceeds from the offering to fund its
current DMD development portfolio, its early-stage DMD discovery work
and DMD-support projects, to fund other non-DMD projects and for working
capital and general corporate purposes.
J.P. Morgan and Citigroup acted as joint book-running managers for the
offering. Leerink Swann acted as lead manager, and Wedbush PacGrow Life
Sciences, KBC Securities and Trout Capital acted as co-managers.
A registration statement relating to this offering was declared
effective by the Securities and Exchange Commission on June 27, 2013.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful, prior to registration or
qualification under the securities laws of any such state or
The offering will be made only by means of a prospectus. A copy of the
preliminary prospectus relating to the offering may be obtained from
J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, New York 11717; telephone: 866-803-9204 or
Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, telephone: 800-831-9146, email: firstname.lastname@example.org.
About Prosensa Holding N.V.
Prosensa is a Dutch biotechnology company engaged in the discovery and
development of RNA-modulating therapeutics for the treatment of genetic
disorders. Its primary focus is on rare neuromuscular and
neurodegenerative disorders with a large unmet medical need, including
Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease.
Prosensa Holding N.V.
Celia Economides, Director IR &
Phone: +1 917 941 9059
Life Sciences (European Media)
Sue Charles, Melanie
Toyne Sewell, VeronicaSellar
Phone: +44 20 7457 2020
Partners (US Media)
Fern Lazar, Hollister Hovey
+1 212 867 1762
Source: Prosensa Holding N.V.
News Provided by Acquire Media
Close window | Back to top